Journal of Clinical Oncology
Articles in this Issue
Temporal and spatial expression of CLDN18.2 in gastric cancer and gastroesophageal junction cancer.
4054 Background: Recent studies have demonstrated the promising efficacy of CLDN18.2-targeted therapy in patients with gastric cancer (GC) or gastroesopha...
Revision of staging system for natural killer T-cell lymphoma: A multicenter study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.
7001 Background: Natural killer T-cell lymphoma (NKTCL), characterized by extranodal involvement, challenges the efficacy of the Ann-Arbor staging system...
Potential biomarker of PD-L1 expression phenotypes in tumor and immune cells for combined PD-1 and CTLA-4 blockade therapies in advanced NSCLC.
8524 Background: Pembrolizumab-based chemo-immunotherapies (Pembro) and nivolumab plus ipilimumab-based immunotherapies with or without 2 cycles of chemot...
Risk of pulmonary toxicities in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab: A systematic review and meta-analysis of phase 3 randomized controlled trials.
e24035 Background: Amivantamab is a novel bispecific antibody that inhibits tumor growth by targeting both the epidermal growth factor receptor (EGFR) and...
Disparities in receipt of chemotherapy at the end of life among patients with NSCLC.
e13746 Background: Chemotherapy near end-of-life (EOL) may not prolong survival and can cause unnecessary suffering. Little work has explored disparities...
Characterization of mechanisms driving CD20 loss in patients with relapsed or refractory large B-cell lymphoma treated with glofitamab.
7022 Background: Glofitamab is a CD20xCD3 T-cell engaging bispecific monoclonal antibody that redirects T cells to eliminate malignant B cells in patients...
Obesity and cancer in america: From declining mortality to emerging challenges.
e23072 Background: Obesity is a global epidemic linked to various health issues, including cancer. This study investigates temporal trends in cancer burde...
Trajectories of patient-reported cognitive function and age-related conditions in a longitudinal observational trial of immune checkpoint inhibitor (ICI) treatment: The DiRECT Cohort.
12014 Background: ICIs have become a mainstay in cancer treatment, but their impact on patient-centered side effects such as decline in cognitive function...
Age-specific unmet needs among older patients with cancer enrolled in an outpatient palliative care program: A retrospective analysis.
12096 Background: Older adults with cancer often experience diverse unmet needs. Understanding these needs is crucial for tailoring palliative care interv...
Tumor-informed ctDNA for recurrence and survival prediction in HPV-independent head and neck squamous cell carcinoma.
e18115 Background: Over half of patients with locally advanced, HPV-independent head and neck squamous cell carcinoma (HNSCC) experience recurrence. The d...
A novel application of deep learning (DL)-based MRI with liquid biomarkers for immune effector cell-associated neurotoxicity syndrome (ICANS) after chimeric antigen receptor (CAR) T-cell therapy.
2516 Background: ICANS is a complication of CAR T-cell therapy, yet risk factors and quantitative diagnostic criteria, particularly neuroimaging criteria,...
Machine learning and survival analysis in gallbladder adenocarcinoma (GBA): Key findings.
e16483 Background: GBA accounts for 90% of gallbladder cancers and is challenging to manage owing to its late presentation and varied treatment approaches...
Health-related quality of life (HRQoL) with paclitaxel plus ramucirumab (PTX-RAM) switch maintenance versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: A secondary endpoint of the ARMANI phase 3 randomized trial.
4060 Background: PTX-RAM switch maintenance significantly improved PFS (HR 0.61, 95%CI 0.48–0.79; p = 0.0002) and OS (HR 0.75, 95%CI 0.58–0.96; p = 0.025)...
APP-first as a strategy to increase new patient access and treatment of patients with gastrointestinal malignancies within a cancer center.
1534 Background: Quality cancer care depends on timely and efficient evaluation of patients to determine next steps in treatment. To support this goal, we...
The eREACH study: A randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers.
10502 Background: With FDA approval of targeted therapies in patients with germline BRCA1/2 -related advanced cancers there is a n...
Voids in regulatory guidance for development of theragnostic radiopharmaceuticals in oncology.
e23044 Background: A new generation of targeted anticancer radiopharmaceuticals is experiencing rapid advancement and increased clinical evaluation. Howev...
Prevalence and characteristics of KRAS-G12D mutations in patients with solid malignancies.
e15027 Background: The KRAS mutations are among the most common genetic mutations found in cancer. Novel KRAS-G12D inhibitors have recently shown potent a...
Implementation of pan-cancer universal germline testing in an ethnically diverse and rural community oncology practice.
10569 Background: Universal germline genetic testing (GGT) is increasingly utilized in precision cancer care. There is limited data on this approach in pa...
Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: A prospective, randomized controlled trial (SPRING-01).
3519 Background: Neoadjuvant short-course radiotherapy (SCRT) combined with chemotherapy as total neoadjuvant therapy (TNT) increases the pathological com...
Efficacy of regorafenib following first-line immune checkpoint inhibitor failure in patients with advanced hepatocellular carcinoma: A multicenter retrospective study.
e16166 Background: Hepatocellular carcinoma (HCC) remains a significant global health challenge While immune checkpoint inhibitors (ICIs) have become stan...
Phase II trial of trametinib in patients with advanced solid tumors harboring genomic alterations in the MAPK pathway: Results from the BELIEVE trial (NCCH1901).
3111 Background: The MAPK pathway is one of the most mutated oncogenic pathways in solid tumors. However, effective treatments targeting this pathway have...
A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.
TPS8664 Background: The additionof antiangiogenic agents to standard first-line treatment with a programmed cell death protein 1 (PD-1) inhibitor and plat...
Impact of active cancer on mortality and complications after TAVR: A systematic review and meta-analysis.
e24024 Background: Patients with active cancer undergoing trans catheter aortic valvular replacement (TAVR) face a higher risk of adverse outcomes due to...
RC108 in combination with furmonertinib in patients with locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) with MET overexpression: Results from a phase Ib/II trial.
8592 Background: Patients (pts) who have progressed on EGFR-TKI treatment have limited treatment choices when accompanied by MET overexpression. RC108 is...
eHealth disease educational intervention vs. outpatient palliative care as usual among incurable cancer patients cared by family caregivers at home.
12062 Background: To determine whether ehealth disease educational interventions (eDEI) with fast-delivering interfaces and concise key messages can enhan...